2019
Validation of the all-comers design: Results of the TARGET-AC substudy
G Toth G, Lansky A, Baumbach A, Kelbæk H, van Royen N, Holmvang L, Janssens L, Brugaletta S, Barbato E, Maillard L, Kiemeneij F, Naber CK, Pucher F, Laursen PN, Ameloot K, Robles C, Milkas A, Sevilla J, Jensen C, Wijns W. Validation of the all-comers design: Results of the TARGET-AC substudy. American Heart Journal 2019, 221: 148-154. PMID: 31924299, DOI: 10.1016/j.ahj.2019.10.019.Peer-Reviewed Original ResearchConceptsComers designRisk factorsNon-ST elevation acute coronary syndromeElevation acute coronary syndromeNER groupReal-world clinical practiceGroup more patientsInternational multicentre registrySignificant valvular diseaseST-elevation infarctionAcute coronary syndromeChronic total occlusionWorld clinical practiceLow inclusion rateMulticentre registryThrombotic stenosisCoronary syndromePrimary PCIStable anginaAngiographic parametersComers populationPatient demographicsStable patientsStudy nursesMore patients
2003
Beta radiation in lesions > 15 mm: a START subgroup.
Heuser R, Laskey W, Lansky A, Popma J, Bonan R. Beta radiation in lesions > 15 mm: a START subgroup. Journal Of Invasive Cardiology 2003, 15: 641-3. PMID: 14608136.Peer-Reviewed Original ResearchConceptsPlacebo groupLong lesionsStent restenosisSTART trialMajor adverse cardiac eventsAngiographic lesion characteristicsIntracoronary beta radiationAdverse cardiac eventsBinary restenosis rateIncidence of recurrentMean lesion lengthSignificant reductionLesion revascularizationRecurrent restenosisVessel revascularizationAngiographic parametersCardiac eventsClinical restenosisPatient demographicsRestenosis rateCoronary lesionsStent thrombosisLesion characteristicsRadiation groupRadiation therapy